EU cracks down on blood pressure medicine made by Mylan

European Union authorities on Monday stepped in to effectively ban sales of blood pressure medicine valsartan made by an India-based unit of Mylan NV after some batches were found to contain a probable cancer-causing impurity, the latest in a global crackdown.

The European regulator said the unit’s compliance certificate had been suspended, effectively prohibiting the use of its valsartan in medicines in the region.

The affected batches are being recalled and tests conducted to determine the extent of the contamination, the European Medicines Agency said https://www.ema.europa.eu/en/news/valsartan-mylan-laboratories-india-can-no-longer-be-used-eu-medicines-due-ndea-impurity on Monday.

The batches were found to contain N-nitrosodiethylamine (NDEA), a probable carcinogen, and were made in Mylan’s Hyderabad facility in India, the EMA said.

Cancer-causing impurities have been linked to batches of valsartan over the past year, leading to a global recall.

The U.S. Food and Drug Administration last month halted imports of drug ingredients or medicines made with ingredients produced at a factory belonging to a Chinese bulk manufacturer of valsartan, Zhejiang Huahai Pharmaceuticals .

Huahai has recalled valsartan products made at its factory in China’s Chuannan province after N-nitrosodimethylamine (NDMA), another impurity linked to cancer, was found.

Mylan did not immediately respond to a request for comment.

(Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)

  • Related Posts

    • Pharma
    • July 24, 2025
    • 267 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 331 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra